Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts Sells 600 Shares

Penumbra, Inc. (NYSE:PEN) EVP Johanna Roberts sold 600 shares of the stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $214.14, for a total value of $128,484.00. Following the completion of the transaction, the executive vice president now owns 63,037 shares in the company, valued at approximately $13,498,743.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Johanna Roberts also recently made the following trade(s):

• On Monday, October 2nd, Johanna Roberts sold 600 shares of Penumbra stock. The stock was sold at an average price of $237.82, for a total value of $142,692.00.
• On Friday, September 1st, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $265.11, for a total transaction of $159,066.00.

Penumbra Price Performance

Shares of NYSE:PEN opened at $223.67 on Friday. The company has a market capitalization of $8.63 billion, a P/E ratio of 217.16 and a beta of 0.58. The company’s 50-day moving average is $224.84 and its 200 day moving average is $274.29. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.41 and a current ratio of 5.99. Penumbra, Inc. has a fifty-two week low of $180.93 and a fifty-two week high of $348.67.

Analysts Set New Price Targets

PEN has been the topic of a number of recent research reports. StockNews.com assumed coverage on shares of Penumbra in a research note on Thursday, October 5th. They issued a “hold” rating on the stock. Citigroup dropped their price target on shares of Penumbra from $390.00 to $320.00 and set a “buy” rating on the stock in a research report on Monday, October 2nd. Canaccord Genuity Group decreased their price objective on Penumbra from $351.00 to $322.00 and set a “buy” rating for the company in a report on Wednesday, August 2nd. Morgan Stanley dropped their target price on Penumbra from $265.00 to $240.00 and set an “equal weight” rating on the stock in a report on Friday, November 3rd. Finally, TheStreet downgraded Penumbra from a “c” rating to a “d+” rating in a report on Thursday, November 2nd. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $317.25.

Institutional Investors Weigh In On Penumbra

Large investors have recently added to or reduced their stakes in the company. FMR LLC increased its stake in shares of Penumbra by 1.3% in the first quarter. FMR LLC now owns 5,619,517 shares of the company’s stock worth $1,566,103,000 after purchasing an additional 72,178 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Penumbra by 2.0% during the third quarter. Vanguard Group Inc. now owns 3,407,434 shares of the company’s stock worth $646,050,000 after acquiring an additional 68,266 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Penumbra by 104.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,185,062 shares of the company’s stock worth $608,956,000 after acquiring an additional 1,115,176 shares during the period. State Street Corp grew its position in shares of Penumbra by 1.5% in the second quarter. State Street Corp now owns 1,061,701 shares of the company’s stock valued at $365,289,000 after purchasing an additional 16,028 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Penumbra by 6.7% during the 2nd quarter. Geode Capital Management LLC now owns 552,423 shares of the company’s stock valued at $190,067,000 after purchasing an additional 34,618 shares during the period. Hedge funds and other institutional investors own 88.18% of the company’s stock.

About Penumbra

Penumbra, Inc, together with its subsidiairies, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, SENDit, and PX SLIM brands.